.jpg "KakaoTalk_20240318_135254429_04(2).jpg")
CHAMEDITECH is continuously carrying out activities to increase its share of the global aesthetics market.
On March 16, CHAMEDITECH held the ‘CHAMEDITECH Global Expert Meeting – Turkiye’ at ‘KohIkSoo Plastic Surgery’ in Seoul. At this event, CHAMEDITECH invited about 20 medical staff and industry officials who are KOLs (Key Opinion Leaders) of Nurederm, a global aesthetic distribution company in Turkiye, to educate the latest filler treatment technology and prevention of side effects.
This lecture, conducted by Koh-Ik soo, a plastic surgeon, included theoretical lectures on the side effects that can occur from filler procedures, such as delayed immune response, necrosis, and blindness, as well as CHAMEDITECH's HA (hyaluronic acid) filler, 'Dorothy'. and 'HYAFILIA ME:DAM' were demonstrated live to promote the excellence of CHAMEDITECH's products.
'Dorothy' is a product that has optimized physical properties to improve fine wrinkles through more than 10 years of research by CHAMEDITECH. This product contains 20mg of high-dose hyaluronic acid (HA) and is sought after by many overseas consumers as its maintenance period is shorter than other products that provide a watery glow. 'HYAFILIA ME:DAM' is CHAMEDITECH's hyaluronic acid filler brand. It has high cohesion, has an excellent wrinkle improvement effect, and is highly safe and sustainable after treatment.
According to KOTRA Middle East medical device market trends, Turkiye has the world's 18th largest aesthetic medical market and is growing steadily every year. On the other hand, due to the lack of domestic industrial base, most of the demand is dependent on imports, so the growth potential is high.
CHAMEDITECH is continuously carrying out activities to expand its share of the global aesthetic market, including Turkiye. Participated in the dermatology specialist conference 'A'DAN Z'YE ESTETiK ZiRVESi 2024' held in Turkiye Antalya from February 29th to March 3rd, operated an exhibition booth and presented 'Dorothy's Guide' to local dermatologists. 'Skin Quality Improvement Methods and Results' lecture was held on and actively promoted CHAMEDITECH's products.
Kim Sok-jin, CEO of CHAMEDITECH, said, “We will conduct active marketing targeting medical staff and industry officials from around the world to expand our market share,” and added, “We will build our reputation as a global bio-aesthetics specialist and solidify our market position.”
CHAMEDITECH produces core raw materials for pharmaceutical supplements, medical devices, and cosmetics using various growth factors, peptides, and natural extracts. We produce and sell professional medical devices such as cosmetic fillers and anti-adhesion agents based on hyaluronic acid cross-linking technology developed through our own research. Following HYAFILIA, we are expanding our presence in the global market by kickstarting sales and marketing of HA fillers such as ME:DAM and Dorothy.